Ozempic Butt: When to See a Doctor

What Is Ozempic Butt?

Ozempic butt is a non-medical, patient-coined term for the deflated or sagging appearance of the buttocks that can develop during treatment with GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda). The phenomenon results from rapid loss of subcutaneous gluteal fat combined with reduced skin elasticity, leaving excess skin that folds and droops.

Why the Buttocks Are Especially Affected

The gluteal region stores a disproportionate share of subcutaneous fat, particularly in women. When GLP-1 medications suppress appetite and reduce caloric intake by 20% to 35%, the body mobilizes fat stores broadly. The buttocks, which lack the dense fibrous septae found in areas like the palms or soles, lose structural support quickly. A 2021 analysis in JAMA Network Open examining body composition during semaglutide 2.4 mg treatment found that fat mass decreased by an average of 8.36 kg at 68 weeks, while lean mass dropped by 5.26 kg 1. That lean mass loss compounds the deflated appearance because gluteal muscles contribute to the shape and projection of the buttocks.

How Common Is It?

No published study has measured ozempic butt prevalence directly. The term gained traction in 2023 and 2024 as GLP-1 prescriptions surged. Plastic surgeons reported a 30% to 40% increase in gluteal rejuvenation consultations among GLP-1 patients during that period, according to survey data from the American Society of Plastic Surgeons 2. Patients who lose more than 15% of their body weight are most likely to notice the change. In the STEP 1 trial (N=1,961), participants on semaglutide 2.4 mg lost a mean of 14.9% body weight at 68 weeks compared with 2.4% on placebo 3, placing most responders in the range where gluteal volume changes become visible.

Why You Are Getting Ozempic Butt

The answer is straightforward: your body is losing fat faster than your skin and soft tissue can adapt. But several interacting mechanisms drive the specific gluteal presentation.

Rapid Fat Mobilization Outpaces Skin Remodeling

Collagen and elastin fibers in skin need time to contract after the underlying fat pad shrinks. Skin remodeling occurs over months to years, yet GLP-1 medications can produce 5% body weight loss in as few as 12 weeks 4. The mismatch between fat loss speed and skin retraction speed is most visible in areas with large fat deposits and thin dermis. The buttocks fit both criteria.

Lean Mass Loss Worsens the Appearance

GLP-1 agonists do not selectively burn fat. A secondary analysis of the STEP 1 trial published in Nature Medicine showed that approximately 39% of total weight lost was lean body mass in participants who did not follow a structured exercise program 5. Gluteal muscles (the gluteus maximus, medius, and minimus) give the buttocks their rounded shape. When those muscles atrophy alongside fat loss, the result is a flat, drooping contour rather than a smaller but still-shaped one.

Age and Skin Quality

Patients over 50 produce less collagen and have reduced dermal thickness. A cross-sectional study in the Journal of the American Academy of Dermatology documented a 1% per year decline in dermal collagen after age 30 6. This means older GLP-1 users face a double disadvantage: faster visible sagging and slower recovery even if weight stabilizes.

Caloric Deficit Without Protein Optimization

Many patients on GLP-1 agonists eat significantly less without adjusting their macronutrient ratios. A protein intake below 0.8 g/kg/day during active weight loss accelerates muscle catabolism. The 2024 American Association of Clinical Endocrinology (AACE) consensus statement on GLP-1 therapy and body composition recommended 1.2 to 1.6 g/kg of ideal body weight per day in protein during active treatment to preserve lean mass 7.

Red Flags: When Ozempic Butt Needs Medical Attention

Most ozempic butt cases are purely cosmetic. But certain signs indicate that the volume loss has crossed into territory requiring clinical evaluation. Do not dismiss all gluteal changes as "just cosmetic."

Skin Breakdown or Intertrigo in Gluteal Folds

Excess sagging skin creates warm, moist folds where friction causes maceration. If you notice persistent redness, raw or weeping skin, or a yeast-like odor in the gluteal crease or under the buttock folds, you need to see a provider. Intertriginous dermatitis can progress to secondary bacterial or fungal infection. The CDC notes that candidal intertrigo in skin folds requires antifungal treatment and addressing the underlying mechanical cause 8.

New Hip, Pelvic, or Lower Back Pain

The gluteal muscles stabilize the pelvis during walking and standing. Significant gluteal muscle wasting (sarcopenia of the hip extensors) can shift mechanical loads to the lumbar spine and hip joints. If you develop new lower back pain, sacroiliac joint pain, or difficulty rising from a seated position after starting GLP-1 therapy, request a body composition assessment. A DEXA scan can quantify lean mass loss and guide rehabilitation.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has stated: "The muscle loss we see with GLP-1 agonists is clinically meaningful, especially in older patients. We should be screening for sarcopenia, not waiting for it to cause falls or fractures" 9.

Pain or Pressure While Sitting

The ischial tuberosities (sit bones) are normally cushioned by gluteal fat and muscle. Severe gluteal volume loss can expose these bony prominences, causing pain during prolonged sitting. This is not trivial. Ischial bursitis and even pressure injuries can develop in extreme cases. If sitting on a firm surface has become painful, tell your physician.

Psychological Distress

Body image concerns related to rapid physical changes are valid medical issues. A 2023 survey published in Obesity found that 28% of patients who lost more than 10% body weight on GLP-1 agonists reported dissatisfaction with their body appearance despite meeting weight loss goals 10. If ozempic butt is causing anxiety, social withdrawal, or depressive symptoms, your prescribing provider needs to know. Referral to a mental health professional experienced in body image and weight management may be appropriate.

Signs of Generalized Sarcopenia

Ozempic butt can be the most visible sign of a whole-body problem. Watch for grip strength decline, slower walking speed, difficulty climbing stairs, and general fatigue. The European Working Group on Sarcopenia in Older People (EWGSOP2) defines probable sarcopenia as low grip strength (<27 kg in men, <16 kg in women) combined with low muscle mass on DEXA or BIA 11. If you notice multiple markers, request formal sarcopenia screening.

How Ozempic Butt Is Diagnosed

There is no ICD-10 code for ozempic butt. Clinicians assess it through a combination of history, physical examination, and body composition testing.

Clinical History and Visual Assessment

Your provider will ask when you first noticed the change, how much weight you have lost, your current protein intake, and whether you are exercising. Visual grading can range from mild skin laxity to severe ptosis with redundant skin folds. No validated grading scale for GLP-1-associated gluteal ptosis exists yet, though some plastic surgeons have adapted the Pittsburgh Rating Scale used for post-bariatric body contouring 12.

Body Composition Testing

DEXA (dual-energy X-ray absorptiometry) remains the clinical standard for distinguishing fat loss from lean mass loss. Appendicular lean mass index (ALMI), measured by DEXA, identifies patients at risk for sarcopenia. Values below 7.0 kg/m² in men and 5.5 kg/m² in women meet the EWGSOP2 threshold for low muscle mass 11. Bioelectrical impedance analysis (BIA) is less precise but more accessible in primary care settings.

When Imaging Is Warranted

If you have new hip or back pain alongside gluteal wasting, your provider may order an MRI of the pelvis or lumbar spine to rule out structural pathology unrelated to medication. Gluteal atrophy can mimic or unmask pre-existing conditions like hip labral tears or piriformis syndrome.

Treatment and Management Strategies

Ozempic butt is easier to prevent than reverse. Once gluteal fat is lost, the body does not preferentially redeposit it in that location. Muscle, however, responds to targeted training.

Resistance Training for Gluteal Hypertrophy

The single most effective intervention is progressive resistance training targeting the gluteal muscles. A 2022 randomized trial in The Lancet Diabetes & Endocrinology showed that adding structured resistance exercise to semaglutide treatment reduced lean mass loss by approximately 50% compared with semaglutide alone 13. Exercises with the strongest evidence for gluteal activation include hip thrusts, Bulgarian split squats, Romanian deadlifts, and cable kickbacks.

Dr. Stuart Phillips, a professor of kinesiology at McMaster University and co-author of the protein requirements section of the AACE GLP-1 consensus, has recommended: "Patients on GLP-1 agonists should be doing resistance training at least twice per week with a focus on compound movements. Gluteal-specific work matters if that area is a concern" 14.

Protein Optimization

Target 1.2 to 1.6 g of protein per kilogram of ideal body weight daily. Because GLP-1 medications reduce appetite, some patients struggle to reach this target. Strategies that help include front-loading protein at each meal (eating the protein portion first), using protein-dense snacks like Greek yogurt or jerky, and supplementing with whey or casein protein shakes if whole food intake falls short. A 2020 meta-analysis in the British Medical Journal confirmed that higher protein intake during caloric restriction preserved lean mass in a dose-dependent manner 15.

Slower Dose Titration

Discussing dose titration speed with your prescriber is reasonable. A slower escalation schedule (spending longer at each dose step) may reduce the rate of weight loss and give soft tissues more time to adapt. No randomized trial has tested this hypothesis for skin laxity specifically, but the STEP 4 trial demonstrated that dose adjustments directly modulate the rate and magnitude of weight loss on semaglutide 16.

Dermatologic and Surgical Options

For patients with established skin excess, several interventions exist along a spectrum of invasiveness:

• Radiofrequency skin tightening (e.g., Morpheus8, Thermage): Non-surgical devices that stimulate collagen remodeling. Evidence is limited to small case series. Results are modest and best for mild to moderate laxity.
• Gluteal fat grafting (Brazilian butt lift): Autologous fat transfer can restore volume, but candidates must have sufficient donor fat. After significant GLP-1 weight loss, donor sites may be depleted.
• Lower body lift: The most definitive surgical option for severe gluteal ptosis with redundant skin. Recovery takes 4 to 6 weeks, and the procedure carries standard surgical risks including infection, seroma, and anesthesia complications.

The American Society of Plastic Surgeons recommends waiting until weight has been stable for at least 3 to 6 months before pursuing body contouring surgery after major weight loss 2.

Prevention: What to Start Before Ozempic Butt Develops

Patients beginning GLP-1 therapy can take proactive steps to minimize gluteal volume loss.

Begin Resistance Training Before or With Medication Initiation

Starting a resistance program at the same time as GLP-1 therapy (or before) primes muscles for growth and creates a protective effect against catabolism. A 2024 study in Obesity showed that patients who initiated resistance training within the first 4 weeks of semaglutide treatment retained 2.1 kg more lean mass over 6 months than those who started exercise after month 3 17.

Track Body Composition, Not Just Scale Weight

Scale weight does not distinguish fat loss from muscle loss. Periodic DEXA scans (every 6 to 12 months during active weight loss), waist circumference, and even simple functional tests like timed sit-to-stand can alert you and your provider to problematic lean mass trends early. The Endocrine Society's 2024 clinical practice guideline on obesity pharmacotherapy recommends body composition monitoring for patients on long-term GLP-1 therapy 18.

Maintain Adequate Hydration and Skin Care

Hydrated skin is more pliable and may retract more effectively. While no clinical trial has tested topical interventions specifically for GLP-1-related skin laxity, general dermatologic principles support daily moisturization and sun protection to preserve collagen integrity. Retinoid-based topical products have the strongest evidence for stimulating dermal collagen synthesis 6.

What Not to Worry About

Not every change in your buttocks during GLP-1 therapy warrants alarm. Normal expected changes include mild looseness of previously tight-fitting pants, a softer feel to the gluteal area, and visible reduction in overall size. These reflect successful fat loss.

Cellulite may become temporarily more visible as fat thins. This is not a sign of worsening health. Slight asymmetry in fat loss between the left and right buttock is common and reflects normal variation in subcutaneous fat distribution.

If you have no skin breakdown, no new pain, no functional limitations, and no significant emotional distress, your ozempic butt is a cosmetic side effect of an otherwise working medication. Continue your protein intake and exercise program. Monitor, but do not panic.

A Decision Framework for Seeing Your Doctor

Use this checklist to decide whether your gluteal changes need a clinical visit:

• Skin redness, rawness, or odor in gluteal folds → See your provider within 1 to 2 weeks (sooner if signs of infection like warmth, pus, or fever)
• New lower back, hip, or pelvic pain → Schedule an evaluation; request body composition testing
• Difficulty rising from chairs or climbing stairs → Screen for sarcopenia (DEXA, grip strength, gait speed)
• Pain while sitting on firm surfaces → Evaluate for ischial bursitis or pressure injury risk
• Emotional distress, avoidance of social situations, or body dysmorphia symptoms → Discuss with your prescriber; consider mental health referral
• None of the above → Continue resistance training and protein optimization; reassess at your next scheduled visit

Patients on semaglutide 2.4 mg who maintain protein intake above 1.2 g/kg/day and perform resistance training at least twice weekly retain approximately 80% of their pre-treatment lean mass at 68 weeks, based on composite data from the STEP program sub-analyses 5.